Non-ophthalmic clinical trials often overlook critical ocular endpoints, putting timelines, budgets, and outcomes at risk. Whether in early planning or fully underway, understanding the risks and integrating ophthalmic assessments can be the difference between trial success and costly delays.
Key Takeaways:
Key Risk Areas: Identify critical blind spots in your non-ophthalmic trials that could jeopardize compliance and outcomes.
Actionable Strategies: Learn how to integrate ophthalmic assessments at every trial phase—from protocol design to post-marketing.
Industry Insights: Backed by real-world experience, discover proven approaches to maintain compliance, retain participants, and achieve clean data